FILTER

FILTERED INTERVIEW RESULTS

James Gale

CEO, SIGNET HEALTHCARE PARTNERS
Signet Healthcare Partners speaks to GBR about how it is evolving its’ investment portfolio in life sciences.

Emer Leahy

PRESIDENT AND CEO, PSYCHOGENICS
PsychoGenics explains how CNS is attracting unprecedented attention and how its AI-driven phenotypic discovery platforms can help to deliver cures.

Keith Crandell

CO-FOUNDER & MANAGING DIRECTOR, ARCH VENTURE PARTNERS
ARCH Venture Partners explains the secrets to successful innovation in todays’ life sciences.

Daniel J. O’Connor

PRESIDENT & CEO, ONCOSEC MEDICAL INCORPORATED
OnoSec Medical explains how treating cancers with a plasmid-based approach can avoid side effects and work on immunologically cold tumors.

Jorge Nogueira

CEO, DIPHARMA FRANCIS
Dipharma speaks to GBR of how it is adapting to market trends and expanding its geography.

Peter Meath

CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, MIDDLE MARKET, J.P. MORGAN COMMERCIAL BANKING
"While the underlying business model for life sciences companies hasn’t changed as a result of our current environment, we’re seeing that increased capital has been made available to those seeking funding. This makes it an incredibly promising time for the sector."

Timothy J. Miller

PRESIDENT & CEO, FORGE BIOLOGICS
"What we are seeing is a reflection of the power of genetic medicine, where the technology has demonstrated clinical promise, as well as safety. Now, in many aspects, it is up to the manufacturing to catch up as that demand for gene therapy manufacturers far exceeds the capacity."

Lesley Millar-Nicholson

DIRECTOR, MIT TECHNOLOGY LICENSING OFFICE
"MIT spins out over 32 startup companies per year approximately, and we have about 358 companies that are still alive, so the ecosystem is functioning well."

Robert E. Landry

EXECUTIVE VICE PRESIDENT, FINANCE AND CHIEF FINANCIAL OFFICER, REGENERON
Regeneron explains how its capabilities for target discovery and validation are enabled by a series of Regeneron-invented technologies that accelerate, improve and disrupt the traditional drug discovery and development process.

Donna LaVoie

PRESIDENT & CEO, LAVOIEHEALTHSCIENCE
LaVoie Health Science explains how the communication requirements for Biotech companies have evolved significantly.

MACIG

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

MACIG West Africa 2021-2022

PARTNER EVENTS